Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 6, 2005 - Issue 15
Submit an article Journal homepage
102
Views
10
CrossRef citations to date
0
Altmetric
Review

Pharmacogenomics in cardiovascular disease: the role of single nucleotide polymorphisms in improving drug therapy

Ruggiero Mango Department of Biopathology, University of Roma Tor Vergata, Rome, Italy
,
Lucia Vecchione Department of Internal Medicine, University of Roma Tor Vergata, Rome, Italy
,
Barbara Raso Department of Biopathology, University of Roma Tor Vergata, Rome, Italy
,
Paola Borgiani Centre of Excellence for Genomic Studies in Multifactorial Diseases, University of Roma Tor Vergata, Rome, Italy
,
Ercole Brunetti St. Peter Hospital, Fatebenefratelli, Roma, Italy
,
Jawahar L Mehta University of Arkansas for Medical Sciences, Little Rock, USA
,
Renato Lauro Department of Internal Medicine, University of Roma Tor Vergata, Rome, Italy
,
Francesco Romeo Dipartimento di Biopatologia e Diagnostica per Immagini, Università di Roma ‘Tor Vergata’, Viale Montepellier 1 00133 Roma, Italy. [email protected]
&
Giuseppe Novelli Department of Biopathology, University of Roma Tor Vergata, Rome, Italy
 show all
Pages 2565-2576 | Published online: 30 Nov 2005

Bibliography

  • WEBER WW: Pharmacogenetics. Oxford University Press, New York, NY (1997).
  • LINDPAINTER K: Pharmacogenetics and the future of medical practice. Br. J. Clin. Pharmacol (2002) 54(2):221.
  • TATE SK, GOLDSTEIN DB: Will tomorrow's medicines work for everyone? Nat. Genet. (2004) 36(11 Suppl.):534–542.
  • SIEST G, JEANNESSON E, BERRAHMOUNE H et al.: Pharmacogenomics and drug response in cardiovascular disorders. Pharmacogenomics (2004) 5:779–802.
  • NAKAGAWA K, ISHIZAKI T: Therapeutic relevance of pharmacogenetic factors in cardiovascular medicine. Pharmacol Ther. (2000) 86:1–28.
  • EVANS WE, RELLING MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science (1999) 286:487–491.
  • UNDER MW PROUGH RA, VALDES R JR: Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin. Chem. (1997) 43:254–266.
  • NELSON DR, ZELDIN DC, HOFFMAN SM, MALTAIS LJ, WAIN HM, NEBERT DW: Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics (2004) 14:1–18.
  • BACHMANN KA: Genotyping and phenotyping the cytochrome P450 enzymes. Am J Ther. (2002) 9:309–316.
  • MAREZ D, LEGRAND M, SABBAGH N et al.: Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics (1997) 7:193–202.
  • LABBE L, O'HARA G, LEFEBVRE M et al.: Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings. Clin. Pharmacol Ther. (2000) 68:44–57.
  • ZANGER UM, RAIMUNDO S, EICHELBAUM M: Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch. Pharm. (2004) 369:23–37.
  • STUBBINS MJ, HARRIES LW, SMITH G, TARBIT MH, WOLF CR: Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics (1996) 6:429–439.
  • YASAR U, ELIASSON E, DAHL ML, et al.: Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem. Biophys. Res. Commun. (1999) 254:628-631. Erratum in: Biochem. Biophys. Res. Commun. (1999) 258:227.
  • CRESPI CL, MILLER VP: The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics (1997) 7:203–210.
  • TAKANASHI K, TAINAKA H, KOBAYASHI K, YASUMORI T, HOSAKAWA M, CHIBA K: CYP2C9 11e359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics (2000) 10:95–104.
  • AITHAL GP, DAY CP, KESTEVEN PJ, DALY AK: Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet (1999) 353:717–719.
  • HIGASHI MK, VEENSTRA DL, KONDO LM et al.: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA (2002) 287: 1690-1698.
  • TAUBE J, HALSALL D, BAGLIN T: Influence of cytochrome P450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood (2000) 96: 1816-1819.
  • NAKAJIMA M, KWON JT, TANAKA N et al.: Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clin. PharmacoL Ther. (2001) 69:72–78.
  • OSCARSON M, MCLELLAN RA, GULLSTEN H et aL: Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. FEBS Lett. (1999) 460:321–327.
  • PIANEZZA ML, SELLERS EM, TYNDALE RF: Nicotine metabolism defect reduces smoking. Nature (1998) 393:750.
  • OCKENE IS, MILLER NH: Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. American Heart Association Task Force on Risk Reduction. Circulation (1997) 96:3243–3247.
  • FRETLAND AJ, LEFF MA, DOLL MA, HEIN DW: Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms. Pharmacogenetics (2001) 11:207–215.
  • ••Important information regarding theenzyme N-acetyltransferase.
  • WEBER WW, HEIN DW: N-acetylation pharmacogenetics. PharmacoL Rev. (1985) 37:25–79.
  • MANSILLA-TINOCO R, HARLAND SJ, RYAN PJ et al.: Hydralazine, antinuclear antibodies, and the lupus syndrome. Br. Med. J. (1982) 284:936–939.
  • GERLOFF T: Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution. Naunyn Schmiedebergs Arch. Pharm. (2004) 369:69-77. Erratum in: Naunyn Schmiedebergs Arch. Pharm.acoL (2004) 369:268.
  • •An excellent analysis of drug transporters.
  • KUBOTA T, FURUKAWA T, TANINO H et al.: Resistant mechanisms of anthracyclines-pirarubicin might partly break through the P-glycoprotein-mediated drug-resistance of human breast cancer tissues. Breast Cancer (2001) 8:333–338.
  • HOFFMEYER S, BURK O, VON RICHTER O et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. (2000) 97:3473–3478.
  • VERSTUYFT C, SCHWAB M, SCHAEFFELER E et al.: Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur. j Clin. PharmacoL (2003) 58:809–812.
  • HUMMA LM, TERRA SG: Pharmacogenetics and cardiovascular disease: impact on drug response and applications to disease management. Am. J. Health Syst. Pharm. (2002) 59:1241–1252.
  • MEISEL C, GERLOFF T, KIRCHHEINER J et aL: Implications of pharmacogenetics for individualizing drug treatment and for study design./ MoL Med. (2003) 81:154–167.
  • ANDERSON JL, CARLQUIST JF, HORNE BD, MUHLESTEIN JB: Cardiovascular pharmacogenomics: current status, future prospects. J. Cardiovasc. PharmacoL Ther. (2003) 8:71–83.
  • TURNER ST, BOERWINKLE E: Genetics of blood pressure, hypertensive complications, and antihypertensive drug responses. Pharmacogenomics (2003) 4:53–65.
  • CADMAN PE, O'CONNOR DT: Pharmacogenomics of hypertension. Curr. Opin. NephroL Hypertens. (2003) 12:61–70.
  • WANG JG, STAESSEN JA: Genetic polymorphisms in the renin-angiotensin system: relevance for susceptibility to cardiovascular disease. Eur. j PharmacoL (2000) 410:289–302.
  • GAINER JV, HUNLEY TE, KON NADEAU JH, MULDOWNEY JA III, BROWN NJ: Angiotensin II Type I receptor polymorphism in African Americans lower frequency of the C1166 variant. Biochem. MoL Biol. Int. (1997) 43:227–231.
  • MATERSON BJ, REDA DJ, CUSHMAN WC: Department of Veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Am. J. Hypertens. (1995) 8:189–192.
  • CARSON P, ZIESCHE S, JOHNSON G, COHN JN: Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J. Card. Fail. (1999) 5:178–187.
  • EXNER DV DRIES DL, DOMANSKI MJ, COHN JN: Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N EngL J. Med. (2001) 344:1351–1357.
  • •An analysis of race-based therapeutics.
  • DIEGUEZ-LUCENA JL, ARANDA-LARA P, RUIZ-GALDON M et al.: Angiotensin I-converting enzyme genotypes and angiotensin II receptors. Response to therapy. Hypertension (1996) 28:98–103.
  • DANSER AH, SCHALEKAMP MA, BAX WA et al.: Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation (1995) 92:1387–1388.
  • WINKELMANN BR, RUSS AP, NAUCK M et al.: Angiotensinogen M235T polymorphism is associated with plasma angiotensinogen and cardiovascular disease. Am. Heart J. (1999) 137:698–705.
  • VAN GEEL PP, PINTO YM, VOORS AA et al.: Angiotensin II Type 1 receptor A1166C gene polymorphism is associated with an increased response to angiotensin II in human arteries. Hypertension (2000) 35:717–721.
  • KOHNO M, YOKOKAWA K, MINAMI M et al.: Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors. Am. J. Med. (1999) 106:544–549.
  • OHMICHI N, IWAI N, UCHIDA Y, SHICHIRI G, NAKAMURA Y, KINOSHITA M: Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype. Am. J. Hypertens. (1997) 10:951–955.
  • RIGAT B, HUBERT C, ALHENC-GELAS F, CAMBIEN F, CORVOL P, SOUBRIER F: An insertion/ deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest. (1990) 86:1343–1346.
  • SASAKI M, OKI T, IUCHI A et aL: Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies. J. Hypertens. (1996) 14:1403–1408.
  • PRASAD A, NARAYANAN S, HUSAIN S et al.: Insertion-deletion polymorphism of the ACE gene modulates reversibility of endothelial dysfunction with ACE inhibition. Circulation (2000) 102:35–41.
  • STAVROULAKIS GA, MAKRIS TK, KRESPI PG et al.: Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism. Cardiovasc. Drugs Ther. (2000) 14:427–432.
  • KURLAND L, MELHUS H, KARLSSON J et aL: Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) Trial. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor Type 1 antagonist treatment in hypertensive patients. J. Hypertens. (2001) 19:1783–1787.
  • KURLAND L: The antihypertensive response to irbesartan treatment from a pharmacogenetic perspective. Minerva Med. (2003) 94:251–258.
  • HINGORANI AD, JIA H, STEVENS PA, HOPPER R, DICKERSON JE, BROWN MJ: Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J. Hypertens. (1995) 13:1602–1609.
  • SCHUNKERT H, HENSE HW, GIMENEZ-ROQUEPLO AP et aL: The angiotensinogen T235 variant and the use of antihypertensive drugs in a population-based cohort. Hypertension (1997) 29:628–633.
  • BENETOS A, GAUTIER S, RICARD S et aL: Influence of angiotensin-converting enzyme and angiotensin II Type 1 receptor gene polymorphisms on aortic stiffness in normotensive and hypertensive patients. Circulation (1996) 94:698–703.
  • O'TOOLE L, STEWART M, PADFIELD P, CT-TANNER K: Effect of the insertion/ deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure. Cardiovasc. PharmacoL (1998) 32:988–994.
  • TAKAHASHI T, YAMAGUCHI E, FURUYA K, KAWAKAMI Y: The ACE gene polymorphism and cough threshold for capsaicin after cilazapril usage. Respir. Med. (2001) 95:130–135.
  • MUKAE S, AOKI S, ITOH S, IWATA T, UEDA H, KATAGIRI T: Bradykinin B(2) receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor-related cough. Hypertension (2000) 36:127–131.
  • HUNT SA, BAKER DW, CHIN M et aL: ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult: executive summary a report of the american college of cardiology/american heart association task force on practice guidelines (committee to revise the 1995 guidelines for the evaluation and management of heart failure): developed in collaboration with the International Society for Heart Lung Transplantation; endorsed by the Heart Failure Society of America. Circulation. (2001) 104:2996-3007. American guidelines for chronic heart failure.
  • BRAUNWALD E, ANTMAN EM, BEASLEY JW et al.: ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J. Am. Coll. CardioL (2000) 36:970-1062. Erratum in: J. Am. Coll. CardioL (2001) 38:294–295.
  • GIBBONS RJ, CHATTERJEE K, DALEY J et aL: ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina). Circulation. (1999) 99:2829–2848.
  • RYAN TJ, ANTMAN EM, BROOKS NH et al.: ACC/AHA Guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation. (1999) 100:1016–1030.
  • FUSTER V RYDEN LE, ASINGER RW et al.: ACC/AHVESC Guidelines for the management of patients with atrial fibrillation: executive summary a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation. (2001) 104:2118-2150. American guidelines for atrial fibrillation.
  • PODLOWSKI S, WENZEL K, LUTHER HP et aL: Betal-adrenoceptor gene variations: a role in idiopathic dilated cardiomyopathy?J. Mo/. Med. (2000) 78:87–93.
  • SOFOWORA GG, DISHY V, MUSZKAT M et al.: A common betal-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. Clin. PharmacoL Ther. (2003) 73:366–371.
  • JOHNSON JA, ZINEH I, PUCKETT BJ, MCGORRAY SP, YARANDI HN, PAULY DF: Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin. PharmacoL Ther. (2003) 74:44–52.
  • FUSTER V, BADIMON L, BADIMON JJ, CHESEBRO JH: The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N EngL J. Med. (1992) 326:310–318.
  • COLLER BS: Antiplatelet agents in the prevention and therapy of thrombosis. Ann. Rev. Med. (1992) 43:171–180.
  • ANDRIOLI G, MINUZ P, SOLERO P et al.: Defective platelet response to arachidonic acid and thromboxane A(2) in subjects with Pl(A2) polymorphism of beta(3) subunit (glycoprotein IIIa). Br. J. HaematoL (2000) 110:911–918.
  • MICHELSON AD, FURMAN MI, GOLDSCHMIDT-CLERMONT P et aL: Platelet GP Ma P1(A) polymorphisms display different sensitivities to agonists. Circulation (2000) 101:1013–1018.
  • UNDAS A, SANAK M, MUSIAL J, SZCZEKLIK A: Platelet glycoprotein lila polymorphism, aspirin, and thrombin generation. Lancet (1999) 353:982–983.
  • SZCZEKLIK A, UNDAS A, SANAK M, FROLOW M, WEGRZYN W: Relationship between bleeding time, aspirin and the PlAl /A2 polymorphism of platelet glycoprotein Ma. Br. J. HaematoL (2000) 110:965–967.
  • ROST S, FREGIN A, IVASKEVICIUS V et aL: Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency Type 2. Nature (2004) 427:537–541.
  • LIT, CHANG CY, JIN DY et al.: Identification of the gene for vitamin K epoxide reductase. Nature (2004) 427:541–544.
  • RIEDER MJ, REINER AP, GAGE BF et aL: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl. J. Med. (2005) 352:2285–2293
  • SACKS FM, PFEFFER MA, MOYE LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N EngL J. Med. (1996) 335:1001–1009.
  • DOWNS JR, CLEARFIELD M, WEIS S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA (1998) 279:1615–1622.
  • SHEPHERD J, COBBE SM, FORD I et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N EngL J. Med. (1995) 333:1301–1307.
  • SCHMITZ G, DROBNIK W: Pharmacogenomics and pharmacogenetics of cholesterol-lowering therapy. Clin. Chem. Lab Med. (2003) 41:581–589.
  • TANNE JH: The new word in designer drugs. Br. Med. J. (1998) 316:1930.
  • DRAYNA D: Multiple RFLPs at the human cholesteryl ester transfer protein (CETP) locus. Nucleic Acids Res. (1987) 15:4698.
  • KUIVENHOVEN JA, JUKEMA JW, ZWINDERMAN AH et al.: The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N EngL J. Med. (1998) 338:86–93.
  • BOEKHOLDT SM, SACKS FM, JUKEMA JW et al.: Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation (2005) 111:278–287.
  • DE MAAT MP, JUKEMA JW, YE S et aL: Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. Am. J. CardioL (1999) 83:852–856.
  • WOLF CR, SMITH G: Pharmacogenetics. Br. Med. Bull. (1999) 55:366–386.
  • HAINING RI,, HUNTER AP, VERONESE ME, TRAGER WF, RETTIE AE: Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch. Biochem. Biophys. (1996) 333:447–458.
  • ARNETT DK, DAVIS BR, FORD CE et al.: Pharmacogenetic association of the angiotensin-converting enzyme insertion/ deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation. (2005) 111:3374–3383.
  • CHOU WH, YAN FX, DE LEON J et aL: Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J. Clin. PsychopharmacoL (2000) 20:246–251.
  • VEENSTRA DL HIGASHI MK: Assessing the cost-effectiveness of pharmacogenomics. AAPS Pharmsci. (2000) 2(3):E29.
  • TAYLOR MR, BRISTOW MR: The emerging pharmacogenomics of the beta-adrenergic receptors. Congest. Heart FaiL (2004) 10:281-288. An excellent review regarding the current state of knowledge and understanding of the genetic variation present in the three human ll-adrenergic receptor genes.
  • BLOCHE MG: Race-based therapeutics. N Engl. J. Med. (2004) 351:2049-2057. A comment about the new era of race-based therapeutics.
  • MASOUDI FA, HAVRANEK EP: Race and responsiveness to drugs for heart failure: correspondence. New Engl. J. Med. (2001) 345:767.
  • CACIOPPO JT, HAWKLEY LC: Social isolation and health, with an emphasis on underlying mechanisms. Perspect. BioL Med. (2003) 46(Suppl.):539–552.
  • LAMBA JK, LIN YS, SCHUETZ EG, THUMMEL KE: Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. (2002) 54:1271–1294.
  • KING BP, KHAN TI, AITHAL GP, KAMALI F, DALY AK: Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics (2004) 14:813–822.
  • ••Characterisation of the polymorphismsassociated with the CYP2C9*2 and CYP2C9*3 alleles are the major CYP2C9-related factor affecting warfarin dose in UK Caucasians.
  • DE MORAIS SM, WILKINSON GR, BLAISDELL J et al.: The major genetic defect responsible for the polymorphism of 5-mephenytoin metabolism in humans. J. Biol. Chem. (1994) 269:15419–15422.
  • •A good explanation of metabolism of the anticonvulsant drug mephenytoin.
  • IBEANU GC, GOLDSTEIN JA, MEYER U et al.: Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. j Pharmacol. Exp. Ther. (1998) 286:1490–1495.
  • OSCARSON M, HIDESTRAND M, JOHANSSON I, INGELMAN-SUNDBERG M: A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. Mol PharmacoL (1997) 52:1034–1040.
  • ISHIGURO A, KUBOTA T, SASAKI H,IGA T: A long PCR assay to distinguish CYP2D6*5 and a novel CYP2D6 mutant allele associated with an 11-kb EcoRI haplotype. Clin. Chim. Acta. (2004) 347:217–221.
  • STEEN VM, MOLVEN A. AARSKOG NK, GULBRANDSEN AK: Homologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of human cytochrome P450 CYP2D6 gene. Hum. Mol Genet. (1995) 4:2251–2257.
  • MAREZ D, LEGRAND M, SABBAGH N et al.: Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics (1997) 7:193–202.
  • SHIMADA T, TSUMURA F, YAMAZAKI H, GUENGERICH FP, INOUE K: Characterization of (+/-)-bufuralol hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for CYP2D6. Pharmacogenetic. (2001) 11:143–156.
  • FUKUSHIMA-UESAKA H, SAITO Y, WATANABE H et al.: Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum. Mutat. (2004) 23:100.
  • HAMZEIY H, VAHDATI-MASHHADIAN N, EDWARDS HJ, GOLDFARB PS: Mutation analysis of the human CYP3A4 gene 5' regulatory region: population screening using non-radioactive SSCP. Mutat. Res. (2002) 500:103–110.
  • DAI D, ZELDIN DC, BLAISDELL JA et al.: Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics (2001) 11:597–607.
  • SOYAMA A, SAITO Y, KOMAMURA K et al.: Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame-shift. DrugMetab. Pharmacokinet. (2002) 17:374–377.

Websites

  • http://www.immici.se/CYPalleles/ cyp2d6.htm CYP Allele Nomenclature Committee. Accessed 26 October, 2005.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.